SK18772001A3 - Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie - Google Patents
Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie Download PDFInfo
- Publication number
- SK18772001A3 SK18772001A3 SK1877-2001A SK18772001A SK18772001A3 SK 18772001 A3 SK18772001 A3 SK 18772001A3 SK 18772001 A SK18772001 A SK 18772001A SK 18772001 A3 SK18772001 A3 SK 18772001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- medicament
- thresholds
- figures
- manufacture
- gray scale
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 230000000324 neuroprotective effect Effects 0.000 title claims abstract description 8
- 230000003289 retinoprotective effect Effects 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title claims description 13
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims abstract description 25
- 229960003401 ramipril Drugs 0.000 claims abstract description 25
- 230000004304 visual acuity Effects 0.000 claims abstract description 24
- 230000002207 retinal effect Effects 0.000 claims abstract description 19
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 claims abstract description 18
- 230000004382 visual function Effects 0.000 claims abstract description 17
- 230000000007 visual effect Effects 0.000 claims abstract description 16
- 229960002231 ramiprilat Drugs 0.000 claims abstract description 14
- 201000001119 neuropathy Diseases 0.000 claims abstract description 11
- 230000007823 neuropathy Effects 0.000 claims abstract description 11
- 208000033379 Chorioretinopathy Diseases 0.000 claims abstract description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 10
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 10
- 230000003412 degenerative effect Effects 0.000 claims abstract description 6
- 208000001491 myopia Diseases 0.000 claims abstract description 6
- 230000004379 myopia Effects 0.000 claims abstract description 6
- 206010058990 Venous occlusion Diseases 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 29
- 208000010412 Glaucoma Diseases 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 229960002680 enalaprilat Drugs 0.000 claims description 12
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims description 12
- 108010066671 Enalaprilat Proteins 0.000 claims description 11
- 230000000052 comparative effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000002441 reversible effect Effects 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 7
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 5
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 5
- 238000006317 isomerization reaction Methods 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 229950006323 angiotensin ii Drugs 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 206010019899 Hereditary retinal dystrophy Diseases 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000000304 vasodilatating effect Effects 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 claims 1
- 102100029365 Piwi-like protein 2 Human genes 0.000 claims 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 7
- 108010080213 vascular factor Proteins 0.000 abstract description 7
- 210000001525 retina Anatomy 0.000 abstract description 6
- 230000007170 pathology Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000006872 improvement Effects 0.000 description 21
- 230000035945 sensitivity Effects 0.000 description 21
- 230000004438 eyesight Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 9
- 210000001328 optic nerve Anatomy 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 201000007737 Retinal degeneration Diseases 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 102400000345 Angiotensin-2 Human genes 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000238413 Octopus Species 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 210000001210 retinal vessel Anatomy 0.000 description 3
- 208000014087 Chorioretinal disease Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 2
- 206010039729 Scotoma Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000013534 fluorescein angiography Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000004386 ocular blood flow Effects 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TN99122 | 1999-06-16 | ||
| FR9915359A FR2794975A1 (fr) | 1999-06-16 | 1999-12-06 | Medicaments opthalmologiques neuro et retino-protecteurs |
| PCT/FR2000/001679 WO2000076499A2 (fr) | 1999-06-16 | 2000-06-16 | Medicaments ophtalmologiques neuro-et retino-protecteurs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK18772001A3 true SK18772001A3 (sk) | 2002-04-04 |
Family
ID=26235177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1877-2001A SK18772001A3 (sk) | 1999-06-16 | 2000-06-16 | Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7049340B1 (xx) |
| EP (1) | EP1185255B1 (xx) |
| JP (1) | JP2003501461A (xx) |
| AT (1) | ATE424819T1 (xx) |
| AU (1) | AU6449000A (xx) |
| BR (1) | BR0011714A (xx) |
| CA (1) | CA2376909A1 (xx) |
| CZ (1) | CZ20014516A3 (xx) |
| DE (1) | DE60041765D1 (xx) |
| DK (1) | DK1185255T3 (xx) |
| ES (1) | ES2324200T3 (xx) |
| HU (1) | HUP0201478A3 (xx) |
| MA (1) | MA26798A1 (xx) |
| MX (1) | MXPA01012907A (xx) |
| NO (1) | NO20016088L (xx) |
| PL (1) | PL352365A1 (xx) |
| SI (1) | SI1185255T1 (xx) |
| SK (1) | SK18772001A3 (xx) |
| TR (1) | TR200103665T2 (xx) |
| WO (1) | WO2000076499A2 (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2826276A1 (fr) * | 2001-06-20 | 2002-12-27 | Raouf Rekik | Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| AU2007249399A1 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| TNSN08110A1 (en) * | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| RU2471454C2 (ru) * | 2010-12-14 | 2013-01-10 | Валерий Викторович Педдер | Способ лечения дистрофических заболеваний сетчатки глаза |
| EP2866805A1 (en) * | 2012-06-29 | 2015-05-06 | Raouf Rekik | Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE55911T1 (de) | 1982-12-27 | 1990-09-15 | Schering Corp | Pharmazeutische zusammensetzung. |
| DE3410732A1 (de) | 1984-03-23 | 1985-09-26 | Hoechst Ag, 6230 Frankfurt | Methode zur behandlung des glaukoms |
| US4656188A (en) | 1985-10-09 | 1987-04-07 | Merck & Co., Inc. | Ace inhibitors in macular degeneration |
| JPH05306296A (ja) * | 1992-04-24 | 1993-11-19 | Marino Forum 21 | 魚類由来ペプチドとその製法 |
| AU2089099A (en) | 1998-01-16 | 1999-08-02 | Alcon Laboratories, Inc. | Topical administration of angiotensin-converting enzyme inhibitors |
-
2000
- 2000-06-16 SI SI200031031T patent/SI1185255T1/sl unknown
- 2000-06-16 TR TR2001/03665T patent/TR200103665T2/xx unknown
- 2000-06-16 ES ES00951603T patent/ES2324200T3/es not_active Expired - Lifetime
- 2000-06-16 AU AU64490/00A patent/AU6449000A/en not_active Abandoned
- 2000-06-16 US US10/018,235 patent/US7049340B1/en not_active Expired - Lifetime
- 2000-06-16 DE DE60041765T patent/DE60041765D1/de not_active Expired - Lifetime
- 2000-06-16 WO PCT/FR2000/001679 patent/WO2000076499A2/fr not_active Application Discontinuation
- 2000-06-16 BR BR0011714-5A patent/BR0011714A/pt not_active Application Discontinuation
- 2000-06-16 CA CA002376909A patent/CA2376909A1/fr not_active Abandoned
- 2000-06-16 MX MXPA01012907A patent/MXPA01012907A/es unknown
- 2000-06-16 EP EP00951603A patent/EP1185255B1/fr not_active Expired - Lifetime
- 2000-06-16 CZ CZ20014516A patent/CZ20014516A3/cs unknown
- 2000-06-16 AT AT00951603T patent/ATE424819T1/de active
- 2000-06-16 HU HU0201478A patent/HUP0201478A3/hu unknown
- 2000-06-16 JP JP2001502832A patent/JP2003501461A/ja active Pending
- 2000-06-16 DK DK00951603T patent/DK1185255T3/da active
- 2000-06-16 PL PL00352365A patent/PL352365A1/xx not_active Application Discontinuation
- 2000-06-16 SK SK1877-2001A patent/SK18772001A3/sk unknown
-
2001
- 2001-12-10 MA MA26439A patent/MA26798A1/fr unknown
- 2001-12-13 NO NO20016088A patent/NO20016088L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01012907A (es) | 2003-06-24 |
| NO20016088D0 (no) | 2001-12-13 |
| ATE424819T1 (de) | 2009-03-15 |
| PL352365A1 (en) | 2003-08-25 |
| EP1185255B1 (fr) | 2009-03-11 |
| US7049340B1 (en) | 2006-05-23 |
| TR200103665T2 (tr) | 2002-10-21 |
| CA2376909A1 (fr) | 2000-12-21 |
| HUP0201478A3 (en) | 2004-05-28 |
| JP2003501461A (ja) | 2003-01-14 |
| WO2000076499A3 (fr) | 2001-05-17 |
| SI1185255T1 (sl) | 2009-08-31 |
| DE60041765D1 (de) | 2009-04-23 |
| CZ20014516A3 (cs) | 2002-05-15 |
| EP1185255A2 (fr) | 2002-03-13 |
| BR0011714A (pt) | 2002-03-05 |
| AU6449000A (en) | 2001-01-02 |
| HUP0201478A2 (hu) | 2002-11-28 |
| WO2000076499A2 (fr) | 2000-12-21 |
| MA26798A1 (fr) | 2004-12-20 |
| ES2324200T3 (es) | 2009-08-03 |
| NO20016088L (no) | 2002-02-12 |
| DK1185255T3 (da) | 2009-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1332811C (en) | Treatment of ocular hypertension with class i calcium channel blocking agents | |
| Bresnick | Diabetic maculopathy: a critical review highlighting diffuse macular edema | |
| JP5579079B2 (ja) | 黄斑浮腫治療用ジフルプレドナート点眼剤 | |
| WO2010113753A1 (ja) | ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用 | |
| Cvetkovic et al. | Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension | |
| MX2012007941A (es) | Farmaceutico para impedir o tratar alteraciones acompañadas por angiogenesis ocular y/o permeabilidad vascular ocular elevada. | |
| US5431907A (en) | Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents | |
| US4904649A (en) | Method and solution for treating glaucoma | |
| SK18772001A3 (sk) | Neuroprotektívne a retinoprotektívne oftalmologické liečivo a jeho použitie | |
| Snady-McCoy et al. | Retinopathy associated with acute pancreatitis | |
| Rouland et al. | Timolol 0.1% gel (Nyogel 0.1%®) once daily versus conventional timolol 0.5% solution twice daily: A comparison of efficacy and safety | |
| Winterkorn et al. | Recovery from ocular ischemic syndrome after treatment with verapamil | |
| Krott et al. | Adjunctive hyperbaric oxygenation in macular edema of vascular origin | |
| HU214719B (hu) | Eljárás retinális betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
| EP0968716B1 (en) | Drugs for ameliorating ocular circulatory disorders | |
| JPH08503968A (ja) | 増殖因子と代謝拮抗物質を含有する組成物 | |
| JPH09278653A (ja) | 網膜疾患治療剤 | |
| KR100854058B1 (ko) | 스테로이드를 유효 성분으로 하는 망맥락막 질환 치료제 | |
| KR20020087834A (ko) | 신경보호 및 망막보호 안과용 약물 | |
| EP1485084B9 (en) | Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophthalmic topical use capable of improving the level of l-ascorbic acid in the eye | |
| US20060172977A1 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| Ajibode | Retinopathy of prematurity: a review | |
| Ferris III | Diabetic macular edema | |
| Marc et al. | Ocular toxicity of topical indomethacin eye drops | |
| Bandello et al. | Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy |